134 related articles for article (PubMed ID: 3664531)
1. Antibody-dependent cell-mediated cytotoxicity using a murine monoclonal antibody against human colorectal cancer in cancer patients.
Takamuku K; Akiyoshi T; Tsuji H
Cancer Immunol Immunother; 1987; 25(2):137-40. PubMed ID: 3664531
[TBL] [Abstract][Full Text] [Related]
2. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
3. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
4. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
5. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of autologous blood mononuclear cells used for auto-infusion together with monoclonal antibodies in tumor treatment.
Frödin JE; Pihlstedt P; Lefvert AK; Mellstedt H
Hybridoma; 1987 Dec; 6(6):555-64. PubMed ID: 3325401
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
Pendurthi TK; Parker R; Schlom J; Primus FJ
Int J Cancer; 1990 Dec; 46(6):1021-8. PubMed ID: 2123477
[TBL] [Abstract][Full Text] [Related]
8. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
9. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells.
Abdullah N; Greenman J; Pimenidou A; Topping KP; Monson JR
Cancer Immunol Immunother; 1999 Dec; 48(9):517-24. PubMed ID: 10602889
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma.
Herlyn D; Herlyn M; Steplewski Z; Koprowski H
Eur J Immunol; 1979 Aug; 9(8):657-9. PubMed ID: 499332
[TBL] [Abstract][Full Text] [Related]
11. Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).
Masucci G; Lindemalm C; Frödin JE; Hagström B; Mellstedt H
Hybridoma; 1988 Oct; 7(5):429-40. PubMed ID: 3198133
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.
Shaw DR; Khazaeli MB; Sun LK; Ghrayeb J; Daddona PE; McKinney S; LoBuglio AF
J Immunol; 1987 Jun; 138(12):4534-8. PubMed ID: 3584980
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes.
Ottonello L; Morone P; Dapino P; Dallegri F
Blood; 1996 Jun; 87(12):5171-8. PubMed ID: 8652830
[TBL] [Abstract][Full Text] [Related]
14. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement.
Rosales C; Jeglum KA; Obrocka M; Steplewski Z
Cell Immunol; 1988 Sep; 115(2):420-8. PubMed ID: 3409330
[TBL] [Abstract][Full Text] [Related]
15. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
Christiaansen JE; Sears DW
Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
[TBL] [Abstract][Full Text] [Related]
16. Antibody dependent cell mediated cytotoxicity on human cervical carcinoma cell line, ME-180, with human monoclonal antibody.
Osumi K; Nagao J; Yuasa H; Fujimoto H; Hagiwara H; Kodera Y; Ohno R
Cancer Lett; 1992 Feb; 62(2):179-83. PubMed ID: 1540945
[TBL] [Abstract][Full Text] [Related]
17. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
Posner MR; Elboim HS; Cannon T; Cavacini L; Hideshima T
AIDS Res Hum Retroviruses; 1992 May; 8(5):553-8. PubMed ID: 1381201
[TBL] [Abstract][Full Text] [Related]
18. Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
Tsang KY; Finch MD; Primus FJ; Schlom J
Cancer Immunol Immunother; 1991; 34(1):9-16. PubMed ID: 1836975
[TBL] [Abstract][Full Text] [Related]
19. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.
Steplewski Z; Sun LK; Shearman CW; Ghrayeb J; Daddona P; Koprowski H
Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4852-6. PubMed ID: 3387441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
